- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about REGN
Recent news which mentions REGN
Viatris Just Snagged a Major FDA Approval
March 03, 2022
From Motley Fool
Is Intellia a Good Gene-Editing Stock to Buy Now?
March 03, 2022
From Motley Fool
From Benzinga
From Benzinga
From Benzinga
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
February 25, 2022
From InvestorPlace
7 Low Volatility Stocks to Buy Right Now for Steady Returns
February 24, 2022
From InvestorPlace
Why Kodiak Sciences Stock Is Cratering Today
February 23, 2022
From Motley Fool
KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?
February 23, 2022
From InvestorPlace
Palo Alto Is Leading the Nasdaq Higher, but 1 Biotech Is Getting Crushed Wednesday
February 23, 2022
From Motley Fool
Why Kodiak Sciences Shares Are Plunging Today
February 23, 2022
From Benzinga
Is Moderna the Next Gilead or the Next Regeneron?
February 22, 2022
From InvestorPlace
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
From Benzinga
From Benzinga
3 Top Biotech Stocks to Buy for the Long Haul
February 17, 2022
From Motley Fool
5 Value Stocks To Watch In The Healthcare Sector
February 14, 2022
From Benzinga
From Benzinga
3 Biotech Stocks That Are too Cheap to Ignore
February 10, 2022
From Motley Fool
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
February 10, 2022
From Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
From Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
From Benzinga
10 Biggest Price Target Changes For Tuesday
February 08, 2022
From Benzinga
‘You will not believe what I’ve just found.’ Inside the ivermectin saga: a hacked password, mysterious websites and faulty data
February 07, 2022
From MarketWatch
From Benzinga
Could This New Indication Create a Blockbuster for Pfizer?
February 05, 2022
From Motley Fool
This Will Put a Big Dent in Eli Lilly's and Regeneron's Sales This Year
February 04, 2022
From Motley Fool
COVID-19 treatments raked in billions of dollars in 2021. How will they do this year?
February 04, 2022
From MarketWatch
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales
February 04, 2022
Tickers
REGN
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.